Education
About Us
Working with TipRanks
Follow Us
Biolife Sciences (BLFE)
OTHER OTC:BLFE
Total Valuation
Biolife Sciences has a market cap or net worth of $4.83K. The enterprise value is $311.53K.
Market Cap$4.83K
Enterprise Value$311.53K
Share Statistics
Biolife Sciences has 4,829,364,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,829,364,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biolife Sciences’s return on equity (ROE) is 1.84 and return on invested capital (ROIC) is 248.80%.
Return on Equity (ROE)1.84
Return on Assets (ROA)-17.44
Return on Invested Capital (ROIC)248.80%
Return on Capital Employed (ROCE)1.80
Revenue Per Employee137.23K
Profits Per Employee-422.58K
Employee Count3
Asset Turnover5.66
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Biolife Sciences is ―. Biolife Sciences’s PEG ratio is -0.00189.
PE Ratio―
PS Ratio142.12
PB Ratio-84.85
Price to Fair Value-84.85
Price to FCF-66.09
Price to Operating Cash Flow>-0.01
PEG Ratio-0.00189
Income Statement
In the last 12 months, Biolife Sciences had revenue of 411.69K and earned -1.27M in profits. Earnings per share was -0.02.
Revenue411.69K
Gross Profit-985.00K
Operating Income-1.24M
Pretax Income-1.27M
Net Income-1.27M
EBITDA-1.22M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -49.93K and capital expenditures 0.00, giving a free cash flow of -49.93K billion.
Operating Cash Flow-49.93K
Free Cash Flow-49.93K
Free Cash Flow per Share>-0.01
Dividends & Yields
Biolife Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-52.52
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Biolife Sciences upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Biolife Sciences as a current ratio of 0.09, with Debt / Equity ratio of -27.49%
Current Ratio0.09
Quick Ratio0.09
Debt to Market Cap<0.01
Net Debt to EBITDA-0.13
Interest Coverage Ratio-25.22
Taxes
In the past 12 months, Biolife Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Biolife Sciences EV to EBITDA ratio is -48.15, with an EV/FCF ratio of -66.27.
EV to Sales142.49
EV to EBITDA-48.15
EV to Free Cash Flow-66.27
EV to Operating Cash Flow-66.34
Balance Sheet
Biolife Sciences has $16.00 in cash and marketable securities with $398.00 in debt, giving a net cash position of -$382.00 billion.
Cash & Marketable Securities$16.00
Total Debt$398.00
Net Cash-$382.00
Net Cash Per Share>-$0.01
Tangible Book Value Per Share-$0.01
Margins
Gross margin is -239.25%, with operating margin of -302.17%, and net profit margin of -307.99%.
Gross Margin-239.25%
Operating Margin-302.17%
Pretax Margin-307.99%
Net Profit Margin-307.99%
EBITDA Margin-295.95%
EBIT Margin-295.85%
Analyst Forecast
The average price target for Biolife Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―